FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to a method of treating a malignant neoplasm using a combination, which contains an anti-PD-L1 antibody and a DNA-PK inhibitor — (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxypyridazin-3-yl)-methanol or a pharmaceutically acceptable salt thereof, as well as to a pharmaceutical composition and a kit containing it.
EFFECT: invention is effective for treating malignant neoplasm, which was tested as positive with respect to PD-L1 expression.
20 cl, 10 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AVELUMAB DOSING MODE FOR TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2777363C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
